Abstract: A damper seal received in a cavity of a turbine blade located between a platform and a retention shelf damper seal according to an exemplary aspect of the present disclosure includes, among other things, a central body portion having a first end region, an opposing second end region, and a width. The damper seal further includes a first portion extending from the first end region of the central body portion, and a first end region of the first portion includes first outwardly extending tabs that define a first enlarged portion that has a first width greater than the width of the central body portion and a second portion extending from the opposing second end region of the central body portion.

Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.

Abstract: In accordance with at least one embodiment, a method and apparatus is provided for generating a first pressure wave propagating in a first direction, said first pressure wave adapted to interact with at least a first portion of a plurality of environmental objects and to produce a first response audible to a user, for generating a second pressure wave propagating in a second direction, said second pressure wave adapted to interact with at least a second portion of the plurality of environmental objects and to produce a second response audible to the user; and for causing additional iterations of the first and second pressure waves. In accordance with at least one embodiment, the first pressure wave is initiated with a first abrupt increase in amplitude and the second pressure wave is initiated with a second abrupt increase in amplitude.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.

Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.

Abstract: A planning and search system are described wherein a graph search and segment matching are used to handle very large searches at a higher speed.

Abstract: The present invention relates to heterocyclic compounds that bind to Bcl proteins and inhibit Bcl function, compositions comprising such compounds, and methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

Abstract: Techniques for generating custom objects for content files are described. An apparatus may comprise a logic device arranged to execute a montage application comprising an authoring component operative to generate a tile object for a digital montage, the authoring component to receive a control directive to associate a content file with a presentation tile of a presentation surface of the digital montage, identify a content file type for the content file, and generate the tile object with information from the content file in accordance with the content file type. Other embodiments are described and claimed.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.

Abstract: Provided herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating FAAH-mediated disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.

Abstract: One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof.

Abstract: A method for manufacturing an investment casting core uses a metallic blank having a thickness between parallel first and second faces less than a width and length transverse thereto. The blank is locally thinned from at least one of the first and second faces. The local thinning forms a taper on a leading portion of the RMC. The blank is through-cut across the thickness. The blank is inserted into the leading portion into a slot in a pre-formed ceramic core.

Abstract: In accordance with at least one embodiment, a method and apparatus is provided for generating a first pressure wave propagating in a first direction, said first pressure wave adapted to interact with at least a first portion of a plurality of environmental objects and to produce a first response audible to a user, for generating a second pressure wave propagating in a second direction, said second pressure wave adapted to interact with at least a second portion of the plurality of environmental objects and to produce a second response audible to the user; and for causing additional iterations of the first and second pressure waves. In accordance with at least one embodiment, the first pressure wave is initiated with a first abrupt increase in amplitude and the second pressure wave is initiated with a second abrupt increase in amplitude.

Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.